The graft remains implanted.Therefore, a comprehensive records re-review was conducted.There were no departures noted during records re-review that would negatively impact the manufacturing of xenografts from lot pd18100001.Manufacturing records indicated that serial id (b)(4) met all specifications and release criteria prior to distribution.There is one related complaint for seroma formation for the lot, also associated with the same physician (name not reported at this time).Porcine dermis xenografts undergo a validated sterilization method: tutoplast®, which includes terminal sterilization by gamma irradiation after packaging.To date, our investigation indicates that the reported complications are more likely associated with one or more extrinsic factors, rather than an intrinsic property of the fortiva porcine dermis xenografts.
|
Rti surgical, inc (rti) and tutogen medical (b)(4), a wholly owned subsidiary of rti, received a complaint as part of the fortiva appear trial.The reported complaint indicated that a patient underwent a left nipple conserving mastectomy.Two drains were placed (one in chest wall was removed (b)(6) 2019; one in the axilla was removed on (b)(6) 2019).On (b)(6) 2019 the patient was noted to have developed a hematoma of the left breast.The hematoma was removed on (b)(6) 2019.The patient received antibiotics from (b)(6) 2019 (cefalexin).The complications resolved without residual effects.
|